A case-cohort study of human herpesvirus 8 seropositivity and incident prostate cancer in Tobago

Alicia McDonald, Frank J. Jenkins, Clareann H. Bunker, John W. Wilson, Alan L. Patrick, Joel L. Weissfeld

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: We previously reported a cross-sectional association between the presence of human herpesvirus 8 (HHV-8) serum antibodies and screen-detected prostate cancer in men living in Tobago. In the same study population, we examined the association between HHV-8 seropositivity and incident prostate cancer discovered at later screenings. Methods. In 40-81 year-old men without prostate cancer discovered at initial digital rectal examination (DRE) and prostate-specific antigen (PSA) screening, a case-cohort design measured the association between baseline HHV-8 seropositivity (modified immunofluorescence assay for antibodies against HHV-8 lytic antigens) and incident prostate cancer detected at DRE and PSA screenings three or five years later. Results: Analyses included 486 unique individuals, 96 incident prostate cancer cases, and 415 randomly selected subjects representing an at-risk cohort. By design, the random sub-cohort contained 25 incident prostate cancer cases. In the sub-cohort, the frequency of HHV-8 seropositivity increased across age groupings (40-49 years: 3.5%, 50-59 years: 13.6%, and ≥ 60 years: 22.9%). HHV-8 seropositivity was higher in men with elevated (≥ 4.0 ng/mL) than men with non-elevated PSA at initial screening (30.4% vs. 9.9% seropositive; crude odds ratio (OR) 3.96, 95% confidence interval (CI) 1.53-10.2; age-adjusted OR 2.42, 95% CI 0.91-6.47). HHV-8 seropositivity did not increase incident prostate cancer risk (age-adjusted hazard ratio (HR) 0.88, 95% CI 0.46-1.69). Conclusions: Case-cohort analysis did not identify association between HHV-8 seropositivity and incident prostate cancer. However, analyses uncovered possible association between HHV-8 and PSA (a marker of prostate inflammation). Co-occurrence of HHV-8 seropositivity and PSA elevation may explain cross-sectional association between HHV-8 and PSA screen-detected prostate cancer.

Original languageEnglish (US)
Article number25
JournalInfectious Agents and Cancer
Volume6
Issue number1
DOIs
StatePublished - Dec 8 2011

Fingerprint

Trinidad and Tobago
Human Herpesvirus 8
Prostatic Neoplasms
Cohort Studies
Prostate-Specific Antigen
Digital Rectal Examination
Confidence Intervals
Odds Ratio
Antibodies
Fluorescent Antibody Technique
Prostate

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Oncology
  • Infectious Diseases
  • Cancer Research

Cite this

McDonald, Alicia ; Jenkins, Frank J. ; Bunker, Clareann H. ; Wilson, John W. ; Patrick, Alan L. ; Weissfeld, Joel L. / A case-cohort study of human herpesvirus 8 seropositivity and incident prostate cancer in Tobago. In: Infectious Agents and Cancer. 2011 ; Vol. 6, No. 1.
@article{af342fcb6a80432289ec08998d871d91,
title = "A case-cohort study of human herpesvirus 8 seropositivity and incident prostate cancer in Tobago",
abstract = "Background: We previously reported a cross-sectional association between the presence of human herpesvirus 8 (HHV-8) serum antibodies and screen-detected prostate cancer in men living in Tobago. In the same study population, we examined the association between HHV-8 seropositivity and incident prostate cancer discovered at later screenings. Methods. In 40-81 year-old men without prostate cancer discovered at initial digital rectal examination (DRE) and prostate-specific antigen (PSA) screening, a case-cohort design measured the association between baseline HHV-8 seropositivity (modified immunofluorescence assay for antibodies against HHV-8 lytic antigens) and incident prostate cancer detected at DRE and PSA screenings three or five years later. Results: Analyses included 486 unique individuals, 96 incident prostate cancer cases, and 415 randomly selected subjects representing an at-risk cohort. By design, the random sub-cohort contained 25 incident prostate cancer cases. In the sub-cohort, the frequency of HHV-8 seropositivity increased across age groupings (40-49 years: 3.5{\%}, 50-59 years: 13.6{\%}, and ≥ 60 years: 22.9{\%}). HHV-8 seropositivity was higher in men with elevated (≥ 4.0 ng/mL) than men with non-elevated PSA at initial screening (30.4{\%} vs. 9.9{\%} seropositive; crude odds ratio (OR) 3.96, 95{\%} confidence interval (CI) 1.53-10.2; age-adjusted OR 2.42, 95{\%} CI 0.91-6.47). HHV-8 seropositivity did not increase incident prostate cancer risk (age-adjusted hazard ratio (HR) 0.88, 95{\%} CI 0.46-1.69). Conclusions: Case-cohort analysis did not identify association between HHV-8 seropositivity and incident prostate cancer. However, analyses uncovered possible association between HHV-8 and PSA (a marker of prostate inflammation). Co-occurrence of HHV-8 seropositivity and PSA elevation may explain cross-sectional association between HHV-8 and PSA screen-detected prostate cancer.",
author = "Alicia McDonald and Jenkins, {Frank J.} and Bunker, {Clareann H.} and Wilson, {John W.} and Patrick, {Alan L.} and Weissfeld, {Joel L.}",
year = "2011",
month = "12",
day = "8",
doi = "10.1186/1750-9378-6-25",
language = "English (US)",
volume = "6",
journal = "Infectious Agents and Cancer",
issn = "1750-9378",
publisher = "BioMed Central",
number = "1",

}

A case-cohort study of human herpesvirus 8 seropositivity and incident prostate cancer in Tobago. / McDonald, Alicia; Jenkins, Frank J.; Bunker, Clareann H.; Wilson, John W.; Patrick, Alan L.; Weissfeld, Joel L.

In: Infectious Agents and Cancer, Vol. 6, No. 1, 25, 08.12.2011.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A case-cohort study of human herpesvirus 8 seropositivity and incident prostate cancer in Tobago

AU - McDonald, Alicia

AU - Jenkins, Frank J.

AU - Bunker, Clareann H.

AU - Wilson, John W.

AU - Patrick, Alan L.

AU - Weissfeld, Joel L.

PY - 2011/12/8

Y1 - 2011/12/8

N2 - Background: We previously reported a cross-sectional association between the presence of human herpesvirus 8 (HHV-8) serum antibodies and screen-detected prostate cancer in men living in Tobago. In the same study population, we examined the association between HHV-8 seropositivity and incident prostate cancer discovered at later screenings. Methods. In 40-81 year-old men without prostate cancer discovered at initial digital rectal examination (DRE) and prostate-specific antigen (PSA) screening, a case-cohort design measured the association between baseline HHV-8 seropositivity (modified immunofluorescence assay for antibodies against HHV-8 lytic antigens) and incident prostate cancer detected at DRE and PSA screenings three or five years later. Results: Analyses included 486 unique individuals, 96 incident prostate cancer cases, and 415 randomly selected subjects representing an at-risk cohort. By design, the random sub-cohort contained 25 incident prostate cancer cases. In the sub-cohort, the frequency of HHV-8 seropositivity increased across age groupings (40-49 years: 3.5%, 50-59 years: 13.6%, and ≥ 60 years: 22.9%). HHV-8 seropositivity was higher in men with elevated (≥ 4.0 ng/mL) than men with non-elevated PSA at initial screening (30.4% vs. 9.9% seropositive; crude odds ratio (OR) 3.96, 95% confidence interval (CI) 1.53-10.2; age-adjusted OR 2.42, 95% CI 0.91-6.47). HHV-8 seropositivity did not increase incident prostate cancer risk (age-adjusted hazard ratio (HR) 0.88, 95% CI 0.46-1.69). Conclusions: Case-cohort analysis did not identify association between HHV-8 seropositivity and incident prostate cancer. However, analyses uncovered possible association between HHV-8 and PSA (a marker of prostate inflammation). Co-occurrence of HHV-8 seropositivity and PSA elevation may explain cross-sectional association between HHV-8 and PSA screen-detected prostate cancer.

AB - Background: We previously reported a cross-sectional association between the presence of human herpesvirus 8 (HHV-8) serum antibodies and screen-detected prostate cancer in men living in Tobago. In the same study population, we examined the association between HHV-8 seropositivity and incident prostate cancer discovered at later screenings. Methods. In 40-81 year-old men without prostate cancer discovered at initial digital rectal examination (DRE) and prostate-specific antigen (PSA) screening, a case-cohort design measured the association between baseline HHV-8 seropositivity (modified immunofluorescence assay for antibodies against HHV-8 lytic antigens) and incident prostate cancer detected at DRE and PSA screenings three or five years later. Results: Analyses included 486 unique individuals, 96 incident prostate cancer cases, and 415 randomly selected subjects representing an at-risk cohort. By design, the random sub-cohort contained 25 incident prostate cancer cases. In the sub-cohort, the frequency of HHV-8 seropositivity increased across age groupings (40-49 years: 3.5%, 50-59 years: 13.6%, and ≥ 60 years: 22.9%). HHV-8 seropositivity was higher in men with elevated (≥ 4.0 ng/mL) than men with non-elevated PSA at initial screening (30.4% vs. 9.9% seropositive; crude odds ratio (OR) 3.96, 95% confidence interval (CI) 1.53-10.2; age-adjusted OR 2.42, 95% CI 0.91-6.47). HHV-8 seropositivity did not increase incident prostate cancer risk (age-adjusted hazard ratio (HR) 0.88, 95% CI 0.46-1.69). Conclusions: Case-cohort analysis did not identify association between HHV-8 seropositivity and incident prostate cancer. However, analyses uncovered possible association between HHV-8 and PSA (a marker of prostate inflammation). Co-occurrence of HHV-8 seropositivity and PSA elevation may explain cross-sectional association between HHV-8 and PSA screen-detected prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=82755167816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82755167816&partnerID=8YFLogxK

U2 - 10.1186/1750-9378-6-25

DO - 10.1186/1750-9378-6-25

M3 - Article

VL - 6

JO - Infectious Agents and Cancer

JF - Infectious Agents and Cancer

SN - 1750-9378

IS - 1

M1 - 25

ER -